Published in Anticancer Res on March 15, 1991
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer (1994) 1.55
On the possible causes of the release of material absorbing at 260 m-mu by streptomycin treated E. coli cells (K 12 and B). J Antibiot (Tokyo) (1967) 1.08
[Release of nucleotides and integrity of the bacterial membrane (E. coli K 12)]. Antibiotica (1966) 1.06
Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res (1992) 1.01
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol (1988) 1.01
Lacidipine and josamycin: two new multidrug resistance modulators. Anticancer Res (1995) 0.94
Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity. Eur J Cancer (1994) 0.91
Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs (1993) 0.91
Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer. Anticancer Res (2005) 0.84
A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother (1993) 0.83
Cardiac peroxisomal enzymes and starvation. Free Radic Res Commun (1989) 0.83
The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro. Tumori (1992) 0.83
Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: a preliminary study. Anticancer Res (1995) 0.81
The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ (1998) 0.81
Repair kinetics of DNA, RNA and proteins in the tissues of mice treated with doxorubicin. Arzneimittelforschung (1979) 0.81
Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity. Arzneimittelforschung (1971) 0.81
A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res (1994) 0.80
Haemopoietic effects of 7 alpha, 17 beta dimethyltestosterone. Pharmacol Res Commun (1979) 0.80
Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study. Br J Cancer (1990) 0.79
A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer (1993) 0.79
Lysosomal alterations in heart and liver of mice treated with doxorubicin. Cancer Chemother Pharmacol (1985) 0.79
The in vitro effect of the antineoplastic agent bryostatin 4 on human hematopoietic progenitor cells. Haematologica (1989) 0.79
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients. J Cancer Res Clin Oncol (1989) 0.78
Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma. Anticancer Res (1993) 0.78
Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial. Lung Cancer (2001) 0.78
Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. Eur J Cancer (1994) 0.78
Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res (1994) 0.78
5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study. J Cancer Res Clin Oncol (1998) 0.78
The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res (1998) 0.78
Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study. Anticancer Res (2001) 0.78
Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM). Am J Clin Oncol (1996) 0.78
Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer. Oncology (2002) 0.78
Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma. Cancer Invest (1992) 0.78
Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients. Nucleosides Nucleotides Nucleic Acids (2006) 0.78
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck. J Cancer Res Clin Oncol (1992) 0.78
Analysis of human dysplastic haematopoiesis in long-term bone marrow culture. Blut (1989) 0.77
Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy. In Vivo (1992) 0.77
New derivatives of 2H-1,3-benzoxazine with anti-bacterial activity. Arzneimittelforschung (1965) 0.77
Effect of buthionine sulfoximine on the sensitivity to doxorubicin of parent and MDR tumor cell lines. J Chemother (1994) 0.77
Chemotherapy in head and neck cancer (I): Management of recurrent or metastatic disease. J Chemother (1992) 0.77
Kinetics of in vivo inhibition of tissue cathepsin D by pepstatin A. Int J Biochem (1988) 0.77
In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. J Chemother (2001) 0.77
Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse. Res Commun Chem Pathol Pharmacol (1990) 0.76
Evaluation of antitumor and antimetastatic activity of pepstatin A in some experimental tumor models. J Chemother (1989) 0.76
Effects of multiple doxorubicin doses on mouse cardiac and hepatic catalase. Pharmacol Res Commun (1984) 0.76
Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma. Tumori (1990) 0.76
Does catalase play a role in adriamycin induced cardiotoxicity? Pharmacol Res Commun (1980) 0.76
Effects of doxorubicin on mouse heart catalase. Drugs Exp Clin Res (1987) 0.76
Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer. Med Oncol Tumor Pharmacother (1992) 0.76
Selection of a new multidrug resistant cell line from Friend leukemia cells by short and cyclic exposures to high concentrations of daunorubicin. Haematologica (1992) 0.76
Clodronate in metastatic breast cancer. N Engl J Med (1998) 0.75
Usefulness of oral medroxyprogesterone acetate in the management of cancer-related cachexia-anorexia syndrome. Oncol Rep (1996) 0.75
Changes of the intracellular water space produced by antibacterial drugs in relation to membrane permeability and membrane lesions. Br J Pharmacol (1968) 0.75
Effects of gamma interferon on a B16 melanoma cell line and its doxorubicin-resistant variant. Pharmacol Res (1992) 0.75
Cyclophosphamide plus epidoxorubicin and 5-fluorouracil with folinic acid as a novel treatment in metastatic breast cancer: preliminary results of a phase II study. J Chemother (1991) 0.75
[Analysis of the factors regulating the penetration of Na2 S35 O-4 in E. coli]. Boll Soc Ital Biol Sper (1965) 0.75
Gamma interferon administration differently affects sensitive or doxorubicin resistant P388 leukemia cells; a relationship with antioxidant defenses? Pharmacol Res (1990) 0.75
Isolated myocardiocytes and DNA synthesis: a possible experimental model to predict the in vivo cardiotoxicity. Pharmacol Res (1990) 0.75
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. J Chemother (1991) 0.75
Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy. Anticancer Drugs (1992) 0.75
[Analysis of the effects of hydrocortisone on the discriminative capacity of the rat]. Acta Neurol (Napoli) (1968) 0.75
5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study. J Chemother (1990) 0.75
The influence of multiple treatment with doxorubicin or 4'-deoxy-doxorubicin on the DNA synthesis and morphology of mouse heart. Int J Tissue React (1984) 0.75
[Serial echocardiographic evaluation of subjects treated with adriamycin]. Boll Soc Ital Cardiol (1981) 0.75
Antioxidant defenses in a B16 melanoma line resistant to doxorubicin: an in vivo study. Anticancer Drugs (1991) 0.75
The effectiveness of combination chemotherapy with cisplatinum and etoposide in the treatment of advanced non-small cell lung cancer. J Chemother (1989) 0.75
Combination chemotherapy with cyclophosphamide, doxorubicin and vincristine in the treatment of stage III-IV small-cell lung cancer. J Chemother (1989) 0.75
In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1. Pharmacol Res (1991) 0.75
Morphological changes in the hearts of CD1 mice following chronic treatment with doxorubicin and lonidamine. Res Commun Chem Pathol Pharmacol (1993) 0.75
[Influence of hydroxycortisone on discriminative capacity of rats]. Boll Soc Ital Biol Sper (1966) 0.75
Influence of mitoxantrone on the syntheses of DNA and proteins of mouse tissues. Tumori (1991) 0.75
Subcutaneous recombinant-human-erythropoietin prevents chemotherapy-related anemia in patients with advanced cancer. Int J Oncol (1992) 0.75
A short-term infusion regimen of Cisplatin, 5-Fluorouracil and L-folinic Acid in advanced head and neck-carcinoma. Oncol Rep (1994) 0.75
In vivo effects of doxorubicin and isoproterenol on reduced glutathione and H2O2 production in mouse heart. Res Commun Chem Pathol Pharmacol (1988) 0.75
Experimental techniques for testing the sensitivity of bladder tumours to antineoplastic drugs. Urol Res (1973) 0.75
[On the different capacity of hydroxocobalamin and 5,6-dimethyl-benzimidazole-coenzyme to reduct the harmful effects of corticoids]. Clin Ter (1967) 0.75
[Analysis of some factors responsible for the bactericidic action and resistance to streptomycin of the E. coli cells]. G Ital Chemioter (1975) 0.75
Does catalase play a role in Adriamycin induced cardiotoxicity? Pharmacol Res Commun (1981) 0.75
[A comparison between the absorption after oral administration and the effect produced on animal growth by two new tetracyclines]. Antibiotica (1966) 0.75
[General actions from the oral administration of THAM. 3. Influence of chronic treatment]. Clin Ter (1966) 0.75
Nephrotoxic effects of pepstatin A. An histoenzymologic study. Pharmacol Res (1991) 0.75
The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse. Tumori (1987) 0.75
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. Ann Oncol (2006) 0.75
[On the different capacities of hydroxycobalamin and dimethyl-5,6-benzimidazole-cobamide-coenzyme to reduce some adverse effects of adrenal cortex hormones]. Boll Soc Ital Biol Sper (1966) 0.75
Cisplatin plus vp16 as salvage treatment for advanced breast-carcinoma resistant or recurrent after 1st line chemotherapy for metastatic disease. Oncol Rep (1995) 0.75
Effect of human granulocyte colony stimulating factor (G-CSF) and reduced glutathione (GSH) on drug-induced leukopenia in golden Syrian hamsters. Pharmacol Res (1991) 0.75
3-Triazenopyrroles: synthesis and antineoplastic activity. Farmaco (1993) 0.75
Acute myocardial effects of mitoxantrone in the rabbit. Cancer Treat Rep (1987) 0.75
A phase I-II study on the toxicity and therapeutic efficacy of 5-fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma. J Chemother (1990) 0.75
Effects of verapamil and N-acetylcysteine on doxorubicin or isoproterenol cardiotoxicity in mice. Pharmacol Res (1990) 0.75
Elf regimen in advanced gastrointestinal malignancies - an analysis of its clinical effectiveness and toxicity. Int J Oncol (1994) 0.75
The multipotential hematopoietic growth factors, bryostatins, inhibit human leukemia cell lines in vitro. J Chemother (1989) 0.75
Scientific activity and needs among medical oncology units in sicily: a survey of the italian association of medical oncology. J Chemother (2010) 0.75
Clinical and experimental projects on chemotherapy of bladder tumours. S Afr Med J (1974) 0.75
Antiproliferative and chemomodulatory effects of interferon-gamma on doxorubicin-sensitive and -resistant tumor cell lines. Anticancer Drugs (1993) 0.75
Morphological changes and catalase activity in the hearts of CD 1 mice following acute starvation or single doses of doxorubicin, epirubicin or mitoxantrone. Chemioterapia (1988) 0.75
The in vivo effects of recombinant human erythropoietin on cisdiamminodichloroplatinum-induced anemia in golden Syrian hamsters. In Vivo (1992) 0.75
Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. Am J Clin Oncol (1995) 0.75